![[C] Volcano obtains FDA clearance of its instant wave-Free Ratio modality.pdf](/uploads/r/null/1/b/1/1b17355b3cc198592376885d4dc5e2a631fcb7ae54455d45d0b5572ff8b583c3/d4100c79-d841-4258-987d-ba2dc7613a63-_C__Volcano_obtains_FDA_clearance_of_its_instant_wave-Free_Ratio_modality_142.jpg)
Pièce
Fait partie de UoA 1
590 résultats avec objets numériques
Afficher les résultats avec des objets numériques
![[C] The Value of Ripple Mapping .pdf](/uploads/r/null/0/1/a/01adc88139c7f4c46014587fb9d1fe1fbc9dbc38cdcdd2f100fd779b9dcb50b8/0dffd0bc-5d4f-466d-83c4-f0f337273d41-_C__The_Value_of_Ripple_Mapping__142.jpg)
Pièce
Fait partie de UoA 1
![[F] Case Study Ripple Mapping Dr. Brenyo - YouTube .pdf](/uploads/r/null/9/2/9/929d8fb29ba1409bc17b362a86b01fadcdb19ae8139c0ea37c0baab5020e5533/b25c39c5-177e-484f-a727-bdc18739803b-_E__Case_Study_Ripple_Mapping_Dr._Brenyo_-_YouTube__142.jpg)
Pièce
Fait partie de UoA 1
![[Ci] EMA Orkambi approval documents Approval for use in patients 12 years and older.pdf](/uploads/r/null/c/5/8/c5899e08d80d55921956995ba6877c3eb46975d987de0c6d571fb9cde8bff91b/52f73e0d-7dc5-4b7b-9f47-a8f415418a42-_Ci__EMA_Orkambi_approval_documents_Approval_for_use_in_patients_12_years_and_older_142.jpg)
![[Cii] EMA Orkambi approval documents Approval for use in patients 6 years and older.pdf](/uploads/r/null/0/e/6/0e6ea321eb24fd572a1dab7b64b3bf165cea74705c8afa1478fd0e62a2a60231/75b65d32-fa41-4f2f-83c1-b48de27c6f8b-_Cii__EMA_Orkambi_approval_documents_Approval_for_use_in_patients_6_years_and_older_142.jpg)
![[D] EMA Assessment report.pdf](/uploads/r/null/6/1/b/61bd7e3ace00f4101c3601b1d53bad03a2c9e9b770a336a0d838b82fafdea053/c052d84e-5516-4b95-ad04-c02d9eb3ff73-_D__EMA_Assessment_report_142.jpg)
Pièce
Fait partie de UoA 1
![[Eii] UK Health Service Commissioning Northern Ireland, Department of Health, 29 October 2019 .pdf](/uploads/r/null/6/2/1/6217606d78cb47a70ba649d901098f8dd9cb60aa47299a74fc0b6b6cef5fb5c0/221787e5-dcde-45e4-b712-386be039ba0e-_Eii__UK_Health_Service_Commissioning_Northern_Ireland__Department_of_Health__29_October_2019__142.jpg)
![[Eiii] UK Health Service Commissioning Scottish Health Secretary, 12 September 2019 .pdf](/uploads/r/null/5/3/d/53d65645a7722315d8b8f2e1d86c0e3f4efc6b73b0a7cfeeede93de9264c94fd/9e72b03a-ecce-4260-a9bc-a973970785b5-_Eiii__UK_Health_Service_Commissioning_Scottish_Health_Secretary__12_September_2019__142.jpg)
![[F] EMA kaftrio .pdf](/uploads/r/null/e/7/1/e718639ce1f25e8b7b62407dd199502cb073cccfcbe265476fd637cc865342a1/26696a5e-e76b-4c86-90af-ff4b2bd4aecb-_F__EMA_kaftrio__142.jpg)
Pièce
Fait partie de UoA 1
![[H] Vertex Announces Positive Phase 3 Study for TRIKAFTA.pdf](/uploads/r/null/c/a/0/ca05ddae65956c01b802065aac01743b92db2766c2b9d99a23e7efe24274a27b/87779853-6a4a-4483-812a-ed777fecde5e-_H__Vertex_Announces_Positive_Phase_3_Study_for_TRIKAFTA_142.jpg)
Pièce
Fait partie de UoA 1
![[D] Public Health England. Seasonal influenza vaccine uptake in children of primary school age.pdf](/uploads/r/null/2/d/1/2d1dd44b209ff9ed688ef6d053c1970ad41305cf56690b407ecb27dca2190a02/ed7bf10d-dceb-4768-b79a-837f90311f6a-_D__Public_Health_England._Seasonal_influenza_vaccine_uptake_in_children_of_primary_school_age_142.jpg)
![[Ei] Centers for Disease Control and Prevention. Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices (ACIP) United States, 2018 19.pdf](/uploads/r/null/c/a/5/ca59783c2946e3d00ca83bb5f5bb5bf5ca8bdc5b25ff9e4cb27ae829d7950638/bb78a78a-9ab1-401c-b7df-4ac257ad7664-_Ei__Centers_for_Disease_Control_and_Prevention._Prevention_and_Control_of_Seasonal_Influenza_with_Vaccines_Recommendations_of_the_Advisory_Committee_on_Immunization_Practices__ACIP__United_States__2018_19_142.jpg)
![[Eii] Centers for Disease Control and Prevention. Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices (ACIP) United States, 201819.pdf](/uploads/r/null/c/5/a/c5a7a50c620a17e0b13bbe96a82aad21fe56cdd5fda6ec31158cf2163b3362ad/e8d599b5-c004-4392-9908-574a71f7b071-_Eii__Centers_for_Disease_Control_and_Prevention._Prevention_and_Control_of_Seasonal_Influenza_with_Vaccines_Recommendations_of_the_Advisory_Committee_on_Immunization_Practices__ACIP__United_States__201819_142.jpg)
![[C] Chronic obstructive pulmonary disease in over 16s diagnosis and management. NICE guideline [NG115].pdf](/uploads/r/null/7/b/7/7b75f93c2a5f75f8a851009965aa91f5a27c77a0a79e6c2139ee6e1b8ea8351e/639c985e-1ebe-4764-8c19-379de90d0e40-_C__Chronic_obstructive_pulmonary_disease_in_over_16s_diagnosis_and_management._NICE_guideline__NG115__142.jpg)
![[B] The World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016-2021 Towards Ending Viral Hepatitis.pdf](/uploads/r/null/8/7/0/870d51edc7004d7de0b1edac035d46fded20b514832460d5106bd919c198ae46/4f40505f-1d2d-4813-a49a-4353ca073ead-_B__The_World_Health_Organization__2016_._Global_Health_Sector_Strategy_on_Viral_Hepatitis_2016-2021_Towards_Ending_Viral_Hepatitis_142.jpg)
![[E] GAVI (2018). Hepatitis B Birth Dose Investment Case at the Vaccine Investment Strategy Programme and Policy Committee Meeting.pdf](/uploads/r/null/2/2/3/223cc631a390e6131663fccb2f7324349020e413ed2eb03c6339afac6755ba71/73fc26c1-1c1c-40fd-a61e-a7cf48f3c67d-_E__GAVI__2018_._Hepatitis_B_Birth_Dose_Investment_Case_at_the_Vaccine_Investment_Strategy_Programme_and_Policy_Committee_Meeting_142.jpg)
![[C] Chief Medical Officer Alert .pdf](/uploads/r/null/f/5/5/f552b96795675dd9d559d40bdca73bfe4a70ddd231e8e520d7734f5a3f42947b/3240a802-b3b0-4738-bd89-c37f4e95e6b1-_C__Chief_Medical_Officer_Alert__142.jpg)
Pièce
Fait partie de UoA 1